Latest news with #NATR
Yahoo
4 days ago
- Business
- Yahoo
1 Safe-and-Steady Stock with Exciting Potential and 2 to Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Finding the right balance between safety and returns isn't easy, which is why StockStory is here to help. That said, here is one low-volatility stock that could offer consistent gains and two stuck in limbo. Rolling One-Year Beta: 0.77 Started on a kitchen table in Utah, Nature's Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. Why Are We Cautious About NATR? Flat sales over the last three years suggest it must innovate and find new ways to grow Modest revenue base of $456.6 million gives it less fixed cost leverage and fewer distribution channels than larger companies Earnings per share fell by 20.6% annually over the last three years while its revenue was flat, showing each sale was less profitable Nature's Sunshine's stock price of $14.13 implies a valuation ratio of 18.5x forward P/E. Dive into our free research report to see why there are better opportunities than NATR. Rolling One-Year Beta: 0.45 The first homebuilder to be listed on the NYSE, KB Home (NYSE:KB) is a homebuilding company targeting the first-time home buyer and move-up buyer markets. Why Do We Avoid KBH? Backlog has dropped by 22.9% on average over the past two years, suggesting it's losing orders as competition picks up Earnings per share have dipped by 5.3% annually over the past two years, which is concerning because stock prices follow EPS over the long term Free cash flow margin dropped by 5.5 percentage points over the last five years, implying the company became more capital intensive as competition picked up At $52.29 per share, KB Home trades at 6.6x forward P/E. Read our free research report to see why you should think twice about including KBH in your portfolio, it's free. Rolling One-Year Beta: 0.32 With over 100 million people served across its various businesses and a workforce of more than 400,000, UnitedHealth Group (NYSE:UNH) operates a health insurance business and Optum, a healthcare services division that provides everything from pharmacy benefits to primary care. Why Is UNH a Top Pick? Massive revenue base of $410.1 billion gives it meaningful leverage when negotiating reimbursement rates Share buybacks catapulted its annual earnings per share growth to 13.1%, which outperformed its revenue gains over the last five years ROIC punches in at 21.6%, illustrating management's expertise in identifying profitable investments UnitedHealth is trading at $300.85 per share, or 9.7x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
NATR Q1 Earnings Call: Outperformance Driven by Asia-Pacific and Europe Amid Tariff Uncertainty
Wellness products company Nature's Sunshine (NASDAQ:NATR) announced better-than-expected revenue in Q1 CY2025, with sales up 2% year on year to $113.2 million. The company expects the full year's revenue to be around $457.5 million, close to analysts' estimates. Its non-GAAP profit of $0.25 per share was 51.5% above analysts' consensus estimates. Is now the time to buy NATR? Find out in our full research report (it's free). Revenue: $113.2 million vs analyst estimates of $109.3 million (2% year-on-year growth, 3.6% beat) Adjusted EPS: $0.25 vs analyst estimates of $0.17 (51.5% beat) Adjusted EBITDA: $10.97 million vs analyst estimates of $9.75 million (9.7% margin, 12.5% beat) The company reconfirmed its revenue guidance for the full year of $457.5 million at the midpoint EBITDA guidance for the full year is $41 million at the midpoint, below analyst estimates of $42.98 million Operating Margin: 5.4%, up from 4.2% in the same quarter last year Free Cash Flow was $1.5 million, up from -$1.5 million in the same quarter last year Market Capitalization: $272.9 million Nature's Sunshine's first quarter results were shaped by continued strength in Asia-Pacific and Europe, as well as stabilization efforts in North America. Management credited growth in Japan and Taiwan to strategic marketing, a focus on high-velocity products, and expanded digital offerings, noting that digital sales rose 19% year over year. CEO Terrence Moorehead emphasized that proactive supply chain measures and inventory buildup helped the company manage new tariff risks without immediate price increases to customers. Looking ahead, management reaffirmed its full-year revenue guidance, citing confidence in ongoing demand and the resilience of its supply chain. CFO Shane Jones noted that the company's outlook remains conservative due to macroeconomic volatility and potential tariff impacts, but expects modest gross margin improvement and stable SG&A expenses. Moorehead stated, 'We've tried to do our homework on our end to make sure that we've done everything that we can do to prepare to potential impact of tariffs.' Nature's Sunshine's management focused on operational execution and regional momentum as key drivers behind Q1's performance. Outperformance versus analyst expectations was attributed to international growth, digital expansion, and effective cost controls, while the company's proactive response to tariff risks was a recurring theme. Asia-Pacific momentum: The region saw double-digit local currency growth, with Japan and Taiwan both delivering over 18% sales increases, driven by a targeted marketing mix and growth-focused product strategy. Europe growth strategies: Central Europe's 16% sales rise was supported by the power line product focus and expansion into the Baltic states, illustrating disciplined execution and market development. North America stabilization: Despite a year-over-year decline, North America achieved its third consecutive quarter of sequential order growth, aided by organizational changes and improved digital capabilities. Digital and autoship adoption: Digital sales outpaced the broader supplement industry's growth, and the Subscribe & Thrive autoship program accounted for about 26% of total sales, supporting recurring revenue. Tariff mitigation measures: The company increased raw and finished goods inventory, diversified suppliers, and enforced pricing contracts to minimize tariff exposure and supply chain disruption. Management expects ongoing uncertainty from tariffs and consumer sentiment to shape results this year, but highlights digital growth and cost discipline as key levers. Strategic investments in digital tools and field support are expected to foster resilience and incremental growth across markets. Digital expansion focus: The rollout of new digital toolkits in North America and continued investment in e-commerce capabilities are expected to drive customer acquisition and retention. Inventory and supply chain agility: Elevated inventory levels and supplier diversification are designed to protect margins and service levels if tariff or trade conditions deteriorate. Cost management discipline: Continued scrutiny of SG&A expenses and margin improvement initiatives are projected to support operating profit even in a challenging macroeconomic environment. Brian Holland (Davidson): Asked if guidance assumes a worsening macro backdrop or a continuation of current trends. Management said the midpoint reflects ongoing instability, while the upper end assumes Q1 trends continue. Brian Holland (Davidson): Inquired about the digital toolkit launch timing and risk of order disruption. CEO Moorehead said it remains on track for the second half of the year and will not disrupt practitioner workflows. Susan Anderson (Canaccord Genuity): Asked about sustaining momentum in Europe and Asia given strong recent comps. Management sees continued opportunity but acknowledged tougher comparisons in the back half of the year. Susan Anderson (Canaccord Genuity): Questioned strategies for North America practitioner and retailer channels. Moorehead highlighted new leadership, field fundamentals, and digital tools as key to improving performance. Susan Anderson (Canaccord Genuity): Sought clarity on gross margin and SG&A cadence. CFO Jones expects modest sequential gross margin improvement and steady quarterly SG&A at $40–42 million. In the quarters ahead, the StockStory team will monitor (1) the rollout and practitioner adoption of new digital toolkits in North America, (2) whether Asia-Pacific and Europe can sustain their growth trajectory against tougher year-over-year comparisons, and (3) the effectiveness of inventory and supply chain strategies in mitigating tariff-related cost pressures. We will also watch for evidence that digital and autoship programs continue to drive recurring revenue. Nature's Sunshine currently trades at a forward P/E ratio of 19.2×. At this valuation, is it a buy or sell post earnings? Find out in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
Yahoo
28-04-2025
- Business
- Yahoo
3 Cash-Heavy Stocks in the Doghouse
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability. Just because a business has cash doesn't mean it's a good investment. Luckily, StockStory is here to help you separate the winners from the losers. That said, here are three companies with net cash positions to avoid and some better alternatives instead. Net Cash Position: $70.5 million (33.3% of Market Cap) Started on a kitchen table in Utah, Nature's Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. Why Are We Wary of NATR? Products fail to spark excitement with consumers, as seen in its flat sales over the last three years Subscale operations are evident in its revenue base of $454.4 million, meaning it has fewer distribution channels than its larger rivals Earnings per share fell by 31.3% annually over the last three years while its revenue was flat, showing each sale was less profitable Nature's Sunshine's stock price of $11.45 implies a valuation ratio of 14.5x forward price-to-earnings. If you're considering NATR for your portfolio, see our FREE research report to learn more. Net Cash Position: $100.8 million (2.9% of Market Cap) With over 20,000 team members across 26 global facilities, Plexus (NASDAQ:PLXS) designs, manufactures, and services complex electronic products for companies in aerospace/defense, healthcare, and industrial sectors. Why Are We Hesitant About PLXS? Sales tumbled by 3.6% annually over the last two years, showing market trends are working against its favor during this cycle Earnings per share lagged its peers over the last two years as they only grew by 1.7% annually Low free cash flow margin of 2.9% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders At $126.89 per share, Plexus trades at 17.4x forward price-to-earnings. Read our free research report to see why you should think twice about including PLXS in your portfolio, it's free. Net Cash Position: $310.8 million (30.4% of Market Cap) Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics (NASDAQ:TXG) develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context. Why Should You Sell TXG? Cash-burning tendencies make us wonder if it can sustainably generate shareholder value Push for growth has led to negative returns on capital, signaling value destruction, and its falling returns suggest its earlier profit pools are drying up Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions 10x Genomics is trading at $8.39 per share, or 1.7x forward price-to-sales. Check out our free in-depth research report to learn more about why TXG doesn't pass our bar. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
02-04-2025
- Business
- Yahoo
3 Reasons to Sell NATR and 1 Stock to Buy Instead
Although the S&P 500 is down 1.6% over the past six months, Nature's Sunshine's stock price has fallen further to $11.31, losing shareholders 14.1% of their capital. This was partly due to its softer quarterly results and might have investors contemplating their next move. Is now the time to buy Nature's Sunshine, or should you be careful about including it in your portfolio? Dive into our full research report to see our analyst team's opinion, it's free. Despite the more favorable entry price, we're swiping left on Nature's Sunshine for now. Here are three reasons why there are better opportunities than NATR and a stock we'd rather own. Started on a kitchen table in Utah, Nature's Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. A company's long-term sales performance can indicate its overall quality. Any business can have short-term success, but a top-tier one grows for years. Unfortunately, Nature's Sunshine struggled to consistently increase demand as its $454.4 million of sales for the trailing 12 months was close to its revenue three years ago. This wasn't a great result and is a sign of lacking business quality. With $454.4 million in revenue over the past 12 months, Nature's Sunshine is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers. Analyzing the change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions. Sadly for Nature's Sunshine, its EPS declined by 31.3% annually over the last three years while its revenue was flat. This tells us the company struggled because its fixed cost base made it difficult to adjust to choppy demand. Nature's Sunshine's business quality ultimately falls short of our standards. Following the recent decline, the stock trades at 16.4× forward price-to-earnings (or $11.31 per share). Investors with a higher risk tolerance might like the company, but we think the potential downside is too great. We're fairly confident there are better investments elsewhere. Let us point you toward the most entrenched endpoint security platform on the market. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
11-02-2025
- Business
- Yahoo
Is It Time To Consider Buying Nature's Sunshine Products, Inc. (NASDAQ:NATR)?
While Nature's Sunshine Products, Inc. (NASDAQ:NATR) might not have the largest market cap around , it saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQCM. The recent rally in share prices has nudged the company in the right direction, though it still falls short of its yearly peak. As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value. Is there still an opportunity here to buy? Let's take a look at Nature's Sunshine Products's outlook and value based on the most recent financial data to see if the opportunity still exists. Check out our latest analysis for Nature's Sunshine Products Great news for investors – Nature's Sunshine Products is still trading at a fairly cheap price according to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average. In this instance, we've used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock's cash flows. we find that Nature's Sunshine Products's ratio of 15.63x is below its peer average of 24.38x, which indicates the stock is trading at a lower price compared to the Personal Products industry. What's more interesting is that, Nature's Sunshine Products's share price is quite stable, which could mean two things: firstly, it may take the share price a while to move closer to its industry peers, and secondly, there may be less chances to buy low in the future once it reaches that value. This is because the stock is less volatile than the wider market given its low beta. Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Though in the case of Nature's Sunshine Products, it is expected to deliver a negative earnings growth of -1.3%, which doesn't help build up its investment thesis. It appears that risk of future uncertainty is high, at least in the near term. Are you a shareholder? Although NATR is currently trading below the industry PE ratio, the negative profit outlook does bring on some uncertainty, which equates to higher risk. Consider whether you want to increase your portfolio exposure to NATR, or whether diversifying into another stock may be a better move for your total risk and return. Are you a potential investor? If you've been keeping tabs on NATR for some time, but hesitant on making the leap, we recommend you research further into the stock. Given its current price multiple, now is a great time to make a decision. But keep in mind the risks that come with negative growth prospects in the future. Diving deeper into the forecasts for Nature's Sunshine Products mentioned earlier will help you understand how analysts view the stock going forward. At Simply Wall St, we have the analysts estimates which you can view by clicking here. If you are no longer interested in Nature's Sunshine Products, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
